These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23107970)

  • 1. Low-dose gemcitabine in long infusion: when less is more.
    Zwitter M
    Indian J Cancer; 2012; 49(2):199-201. PubMed ID: 23107970
    [No Abstract]   [Full Text] [Related]  

  • 2. Is long term gemcitabine useful in small cell lung cancer?
    Dediu M
    Lung Cancer; 2002 May; 36(2):217-8. PubMed ID: 11955659
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging role of gemcitabine in lung cancer.
    Bunn PA
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-1. PubMed ID: 9207307
    [No Abstract]   [Full Text] [Related]  

  • 4. [First-line non-small-cell lung cancer: role of gemcitabine].
    Barata F
    Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S20-2. PubMed ID: 16273006
    [No Abstract]   [Full Text] [Related]  

  • 5. Gemcitabine for lung cancer.
    Drug Ther Bull; 1996 Sep; 34(9):71-2. PubMed ID: 8885499
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.
    Postmus PE; Schramel FM; Smit EF
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):79-82. PubMed ID: 9728590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine--a new agent in the treatment of non-small cell lung cancer. A commentary.
    Carmichael J
    Lung Cancer; 1999 Aug; 25(2):73-5. PubMed ID: 10470840
    [No Abstract]   [Full Text] [Related]  

  • 8. Gemcitabine in non-small cell lung cancer.
    Sørensen JB
    Lung Cancer; 1995 Apr; 12 Suppl 1():S173-5. PubMed ID: 7551926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and vascular toxicity.
    Muñoz A; Mañé JM; Rubio I; Fernández R; Fuente N; Barceló R; López Vivanco G
    Lung Cancer; 2002 Aug; 37(2):229. PubMed ID: 12140148
    [No Abstract]   [Full Text] [Related]  

  • 10. Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():5-65. PubMed ID: 8718418
    [No Abstract]   [Full Text] [Related]  

  • 11. The emerging role of gemcitabine in lung cancer: part I.
    Bunn PA
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-1. PubMed ID: 9194472
    [No Abstract]   [Full Text] [Related]  

  • 12. Gemcitabine: current status of phase I and II trials.
    Kaye SB
    J Clin Oncol; 1994 Aug; 12(8):1527-31. PubMed ID: 8040662
    [No Abstract]   [Full Text] [Related]  

  • 13. Lung Cancer Experts' Symposium. Proceedings. Stresa, Italy, October 1997.
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):1-88. PubMed ID: 9728577
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary on "Gemcitabine: single-agent and combination therapy in non-small cell lung cancer". The Oncologist 1999;4:241-251.
    Edelman MJ
    Oncologist; 1999; 4(3):252-5. PubMed ID: 10394592
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract]   [Full Text] [Related]  

  • 16. Gemcitabine--a major advance?
    Thomas A; Steward WP
    Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
    [No Abstract]   [Full Text] [Related]  

  • 17. Veno-occlusive disease of the liver induced by gemcitabine.
    Dobbie M; Hofer S; Oberholzer M; Herrmann R
    Ann Oncol; 1998 Jun; 9(6):681. PubMed ID: 9681086
    [No Abstract]   [Full Text] [Related]  

  • 18. An unusual case of gemcitabine-induced radiation recall.
    Squire S; Chan M; Feller E; Mega A; Gold R
    Am J Clin Oncol; 2006 Dec; 29(6):636. PubMed ID: 17149004
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe neurotoxicity caused by gemcitabine treatment.
    Larsen FO; Hansen SW
    Acta Oncol; 2004; 43(6):590-1. PubMed ID: 15370618
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemolytic-uremic syndrome caused by gemcitabine.
    Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
    Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.